BAM
TTOO

Belpointe Asset Management’s T2 Biosystems, Inc TTOO Stock Holding History

Belpointe Asset Management’s Portfolio TTOO Stock Details TTOO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$230 – 3875
2022
Q4 		$230 Buy
+2
New +$410 ﹤0.01% 3621

Other funds holding TTOO

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belpointe Asset Management's TTOO Position: Q1 2023 in Review

Belpointe Asset Management sold out of T2 Biosystems, Inc (TTOO) in Q1 2023, closing a stake of 2 shares — an estimated $230 sold.

Belpointe Asset Management first reported a position in TTOO in Q4 2022 and held it in 1 quarter. The position peaked at $230 in Q4 2022. 28 funds tracked by Wall St. Rank hold TTOO as of Q1 2023.

  • Belpointe Asset Management reported no remaining T2 Biosystems, Inc position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2 T2 Biosystems, Inc shares in Q1 2023, an estimated $230.
  • Belpointe Asset Management first reported a position in T2 Biosystems, Inc in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's T2 Biosystems, Inc position peaked at $230 in Q4 2022.
  • 28 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.